Overview
- The Dallas startup announced a $200 million seed round and a public launch, naming investors that include Sequoia Capital, In-Q-Tel, ARK Invest, Franklin Templeton, Lux Capital and Neogenesis.
- Founders Ben Lamm and Palmer Luckey conceived the effort and David Spirk was named CEO to lead the company from a defense and biotech background.
- Warhound says its approach is to bank genetic material from proven dogs, clone those animals and screen or edit genes linked to inherited problems such as vision loss and hip dysplasia.
- The company says it will use Colossal-licensed genetics technology and work with Anduril on dog-mounted equipment, but it has no signed customers and gives mixed delivery estimates that include a roughly two-year horizon.
- Warhound cites American Humane guidance for welfare and retirement plans, yet cloning success rates, the efficacy of edits, regulatory approval and acceptance by military procurement remain open and consequential questions for handlers and readiness.